ARTICLE | Strategy

Engineering its engine

June 12, 2006 7:00 AM UTC

By choosing to merge, Amura Ltd. has broadened its capabilities beyond the protease space originally targeted by its small molecule medicinal chemistry platform, while Proteom Ltd. and its in silico screening and drug design technology have been able to escape the fee-for-service rat race.

The newco, Amura Holdings Ltd., will initially look to out-license its programs once they are in preclinical development, but the long term goal is to integrate into an inflammation and immunology drug discovery and development company...